145 related articles for article (PubMed ID: 25862488)
21. FAK and Nanog cross talk with p53 in cancer stem cells.
Golubovskaya VM
Anticancer Agents Med Chem; 2013 May; 13(4):576-80. PubMed ID: 22934707
[TBL] [Abstract][Full Text] [Related]
22. Unraveling the relationship between n-myc and Focal Adhesion Kinase (FAK) in neuroblastoma?
Madonna MB
Cell Cycle; 2010 May; 9(9):1679-80. PubMed ID: 20448460
[No Abstract] [Full Text] [Related]
23. The 7-amino-acid site in the proline-rich region of the N-terminal domain of p53 is involved in the interaction with FAK and is critical for p53 functioning.
Golubovskaya VM; Finch R; Zheng M; Kurenova EV; Cance WG
Biochem J; 2008 Apr; 411(1):151-60. PubMed ID: 18215142
[TBL] [Abstract][Full Text] [Related]
24. Sphingosine kinase 1 promotes tumor progression and confers malignancy phenotypes of colon cancer by regulating the focal adhesion kinase pathway and adhesion molecules.
Liu SQ; Su YJ; Qin MB; Mao YB; Huang JA; Tang GD
Int J Oncol; 2013 Feb; 42(2):617-26. PubMed ID: 23232649
[TBL] [Abstract][Full Text] [Related]
25. The Ews/Fli-1 fusion gene changes the status of p53 in neuroblastoma tumor cell lines.
Rorie CJ; Weissman BE
Cancer Res; 2004 Oct; 64(20):7288-95. PubMed ID: 15492248
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of the focal adhesion kinase and vascular endothelial growth factor receptor-3 interaction leads to decreased survival in human neuroblastoma cell lines.
Beierle EA; Ma X; Stewart JE; Megison M; Cance WG; Kurenova EV
Mol Carcinog; 2014 Mar; 53(3):230-42. PubMed ID: 23065847
[TBL] [Abstract][Full Text] [Related]
27. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
[TBL] [Abstract][Full Text] [Related]
28. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
[TBL] [Abstract][Full Text] [Related]
29. Vascular endothelial growth factor receptor-3 and focal adhesion kinase bind and suppress apoptosis in breast cancer cells.
Garces CA; Kurenova EV; Golubovskaya VM; Cance WG
Cancer Res; 2006 Feb; 66(3):1446-54. PubMed ID: 16452200
[TBL] [Abstract][Full Text] [Related]
30. The neurogene BTG2TIS21/PC3 is transactivated by DeltaNp73alpha via p53 specifically in neuroblastoma cells.
Goldschneider D; Million K; Meiller A; Haddada H; Puisieux A; Bénard J; May E; Douc-Rasy S
J Cell Sci; 2005 Mar; 118(Pt 6):1245-53. PubMed ID: 15741235
[TBL] [Abstract][Full Text] [Related]
31. p53 and Egr-1 additively suppress transformed growth in HT1080 cells but Egr-1 counteracts p53-dependent apoptosis.
de Belle I; Huang RP; Fan Y; Liu C; Mercola D; Adamson ED
Oncogene; 1999 Jun; 18(24):3633-42. PubMed ID: 10380885
[TBL] [Abstract][Full Text] [Related]
32. FAK activity protects nucleostemin in facilitating breast cancer spheroid and tumor growth.
Tancioni I; Miller NL; Uryu S; Lawson C; Jean C; Chen XL; Kleinschmidt EG; Schlaepfer DD
Breast Cancer Res; 2015 Mar; 17():47. PubMed ID: 25880415
[TBL] [Abstract][Full Text] [Related]
33. Activation of focal adhesion kinase enhances the adhesion and invasion of pancreatic cancer cells via extracellular signal-regulated kinase-1/2 signaling pathway activation.
Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
Mol Cancer; 2005 Oct; 4():37. PubMed ID: 16209712
[TBL] [Abstract][Full Text] [Related]
34. Differential sensitivity of chemoresistant neuroblastoma subtypes to MAPK-targeted treatment correlates with ERK, p53 expression, and signaling response to U0126.
Eppstein AC; Sandoval JA; Klein PJ; Woodruff HA; Grosfeld JL; Hickey RJ; Malkas LH; Schmidt CM
J Pediatr Surg; 2006 Jan; 41(1):252-9. PubMed ID: 16410143
[TBL] [Abstract][Full Text] [Related]
35. Focal adhesion kinase promotes the aggressive melanoma phenotype.
Hess AR; Postovit LM; Margaryan NV; Seftor EA; Schneider GB; Seftor RE; Nickoloff BJ; Hendrix MJ
Cancer Res; 2005 Nov; 65(21):9851-60. PubMed ID: 16267008
[TBL] [Abstract][Full Text] [Related]
36. Serine-Threonine Kinase Receptor Associate Protein (STRAP) confers an aggressive phenotype in neuroblastoma via regulation of Focal Adhesion Kinase (FAK).
Bownes LV; Marayati R; Quinn CH; Hutchins SC; Stewart JE; Anderson JC; Willey CD; Datta PK; Beierle EA
J Pediatr Surg; 2022 Jun; 57(6):1026-1032. PubMed ID: 35272839
[TBL] [Abstract][Full Text] [Related]
37. Correlations between the expression, phosphotyrosine content and enzymatic activity of focal adhesion kinase, pp125FAK, in tumor and nontransformed cells.
Withers BE; Hanks SK; Fry DW
Cancer Biochem Biophys; 1996 Apr; 15(3):127-39. PubMed ID: 8937737
[TBL] [Abstract][Full Text] [Related]
38. Deoxycholic acid differentially regulates focal adhesion kinase phosphorylation: role of tyrosine phosphatase ShP2.
Khare S; Holgren C; Samarel AM
Am J Physiol Gastrointest Liver Physiol; 2006 Dec; 291(6):G1100-12. PubMed ID: 16920701
[TBL] [Abstract][Full Text] [Related]
39. Regulation of focal adhesion dynamics and disassembly by phosphorylation of FAK at tyrosine 397.
Hamadi A; Bouali M; Dontenwill M; Stoeckel H; Takeda K; Rondé P
J Cell Sci; 2005 Oct; 118(Pt 19):4415-25. PubMed ID: 16159962
[TBL] [Abstract][Full Text] [Related]
40. Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases.
Shi Q; Bao S; Song L; Wu Q; Bigner DD; Hjelmeland AB; Rich JN
Oncogene; 2007 Jun; 26(28):4084-94. PubMed ID: 17213807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
